Foralumab TZLS-401 100 µg

DRUG2 trials

Sponsors

Brigham and Women's Hospital, Tiziana Life Sciences LTD

Conditions

Alzheimers DiseaseDementiaMild Cognitive Impairment Due to Alzheimer's DiseaseNon-Active Secondary Progressive Multiple Sclerosis

Phase 2

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

RecruitingNCT06489548

Brigham and Women's HospitalAlzheimers Disease, Dementia, Mild Cognitive Impairment Due to Alzheimer's Disease

Start: 2025-09-16End: 2026-12-01Target: 16Updated: 2026-02-12

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

RecruitingNCT06890923

Tiziana Life Sciences LTDNon-Active Secondary Progressive Multiple Sclerosis

Start: 2025-03-04End: 2026-08-30Target: 55Updated: 2025-06-06